19 May 2013
Keywords: SuperGen, Astex Therapeutics, M&A, Cancer
Article | 08 April 2011
USA-based cancer drug developer SuperGen (Nasdaq: SUPG) and privately-held UK biotech firm Astex Therapeutics have entered into a definitive ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
8 April 2011
7 April 2011
17 May 2013
© 2013 thepharmaletter.com